Radiochemicals for research and clinical use
BV Cyclotron VU is a global health science company that produces radiopharmaceuticals and radiochemicals for medical diagnostics and research. Located at the campus of VU University Medical Center in Amsterdam, Cyclotron VU produces GMP- compliant medical isotopes in state-of-the-art manufacturing facilities. These products are used daily by pharmaceutical and biotechnology companies, medical device manufacturers, hospitals, clinics, and research laboratories.
5/7/2014: In a joint effort, researchers from various departments at the University of Groningen, the Netherlands, have recently shown that everolimus, a drug currently used in the treatment of diverse cancer types, reduces the uptake of 89Zr-labeled bevacizumab in patients with neuroendocrine tumors.
13/2/2014: Researchers from the Medical Center of the VU University, Amsterdam, have recently carried out a multicenter evaluation to make the performance of PET/CT procedures using 89Zr uniform across different sites. Their positive results have just been published in the Journal of Nuclear Medicine.
2/8/2013: Last week, researchers at the VU University Medical Center (VUmc) in Amsterdam received a 1-million Euro funding for a multicenter trial in head and neck cancer patients. The funding, granted by KWF/Alpe d’HuZes, will be used by the VUmc to produce 89Zr-radiolabeled antibodies for leading oncological centers in Europe.